Drug Information

General Information
Drug ID
DR00308
Drug Name
Vinblastine
Synonyms
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid; NDC 0002-1452-01; Nincaluicolflastine; Rozevin; VLB; VR-8; Vinblastin; Vinblastina; Vinblastina (TN); Vinblastina [DCIT]; Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum; Vinblastinum [INN-Latin]; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine
Drug Type
Small molecular drug
Indication Testicular cancer [ICD11: 2C80] Approved [1]
Hodgkin lymphoma [ICD11: 2B30] Approved [1]
Bladder cancer [ICD11: 2C94] Approved [1]
Melanoma [ICD11: 2C30] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C46H58N4O9
Canonical SMILES
CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
InChI
InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1
InChIKey
JXLYSJRDGCGARV-CFWMRBGOSA-N
CAS Number
CAS 865-21-4
Pharmaceutical Properties Molecular Weight 811 Topological Polar Surface Area 154
Heavy Atom Count 59 Rotatable Bond Count 10
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 12
XLogP
3.7
PubChem CID
13342
PubChem SID
103229487 , 103924566 , 104331509 , 124886802 , 126628575 , 126690312 , 127342232 , 127342233 , 134338070 , 134980402 , 136126664 , 136959342 , 137001867 , 141857134 , 152104919 , 15945566 , 162184753 , 165280031 , 16702846 , 175268513 , 178103457 , 179335179 , 184812178 , 223683512 , 223832241 , 226395766 , 24262986 , 25641143 , 29281493 , 46393695 , 48034812 , 49855966 , 50104049 , 50637221 , 57328088 , 7891062 , 8160040 , 85788295 , 92718122 , 93167219
ChEBI ID
ChEBI:27375
TTD Drug ID
D0W9MM
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MDR3 Transporter Info Multidrug resistance protein 3 Substrate [3]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [4]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [5]
P-GP Transporter Info P-glycoprotein 1 Substrate [6]
Drug-Transporter Activity Data
Drug-Transporter Activity Data MRP2 Transporter Info Km = 137.3 microM Madin-Darby canine kidney cells (MDCKII)-MRP2 [7]
P-GP Transporter Info Km = 0.8 microM Chinese hamster ovary AA8 cells-MDR1 [8]
P-GP Transporter Info Km = 5.71 microM High five cells-MDR1 [9]
P-GP Transporter Info Km = 19 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [10]
P-GP Transporter Info Km = 89.2 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [11]
P-GP Transporter Info Km = 99.4 microM LLC-PK1 cells-MDR1 [12]
P-GP Transporter Info Km = 253 microM Madin-Darby canine kidney (MDCK) cells-MDR1 [11]
P-GP Transporter Info Km = 146 microM Oocytes-MDR1 [6]
P-GP Transporter Info Km = 1.7 microM Spodoptera frugiperda (Sf9) cells-MDR1 [13]
References
1 Vinblastine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
3 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
4 Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci. 2004 Mar 9;6(1):E8.
5 Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
6 Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84.
7 Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9.
8 Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.
9 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
10 Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem. 1993 Jul 15;268(20):14991-7.
11 Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72.
12 Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.
13 Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.